Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.58 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.49 |
| ▸ | ALPL | P05186 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019762 | 0.86 | ALOX15 (0.60) | ALOX15EIF4A3ALPLADORA3ADORA2A | |
| SCHEMBL25758822 | 0.86 | ALOX15 (0.57) | ALOX15EIF4A3ALPLARADORA3 | |
| SCHEMBL24740347 | 0.84 | ALOX15 (0.61) | ALOX15EIF4A3ALPLARADORA3 | |
| SCHEMBL30310723 | 0.82 | XDH (0.47) | ALOX15EIF4A3ALPLMAPTCDK1 | |
| SCHEMBL7673791 | 0.82 | XDH (0.47) | ALOX15EIF4A3ALPLMAPTCDK1 | |
| SCHEMBL24740100 | 0.81 | ALOX15 (0.58) | ALOX15EIF4A3LMNAPOLBMAPT | |
| SCHEMBL24019772 | 0.81 | ALOX15 (0.53) | ALOX15EIF4A3ALPLARADORA3 | |
| SCHEMBL24019959 | 0.81 | ALOX15 (0.57) | ALOX15ALPLADORA3ADORA2AADORA2B | |
| SCHEMBL24019957 | 0.80 | ALOX15 (0.52) | ALOX15EIF4A3ALPLADORA3ADORA2A | |
| SCHEMBL24019764 | 0.78 | ALOX15 (0.51) | ALOX15EIF4A3ALPLLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | ALOX15 1749/4885EIF4A3 608/4885ALPL 1768/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | ALOX15 1749/4885EIF4A3 608/4885ALPL 1768/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | ALOX15 1455/4885EIF4A3 582/4885ALPL 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.